ClinicalTrials.gg
CompletedNCT07335536Updated Oct 16, 2026

The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval

An interventional study of remimazolam-alfentanil combination and propofol-alfentanil in Hypoxia, Infertility and Infertility Assisted Reproductive Technology, sponsored by Diansan Su. Completed at 2 sites in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Diansan Su · Not applicable, Interventional, and Prevention

How we know

Updated Oct 16, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in Hypoxia with a site in China — 44 open to participants now, 45 under way, none of them phase 3. Hypoxia · China.

Enrollment
32nd of 78
400 · median 240
Started
2025
with 21 others
No phase
63 of 97
31 open now
Registered
69th of 97
by date
Lead sponsor
2 of 97
Diansan Su

Among the 97 studies in Hypoxia with a site in China, this one is the 32nd largest by enrollment of the 78 interventional ones that give a count, is one of 22 that started in 2025, is one of 63 with no phase, and was the 69th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

44 of the 97 studies in Hypoxia with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Hypoxia with a site in China, or all of them as a file.
02

Study summary

Hypoxia is the most common adverse reaction during sedation outside the operating room.Exploring novel drug combinations to reduce the incidence of hypoxia during sedation in patients undergoing transvaginal oocyte retrieval procedures enhances patient safety and lowers perioperative adverse event rates. This multicenter, prospective, randomized, controlled clinical study will compare the hypoxia incidence rate of the remimazolam-alfentanil combination against the commonly used propofol-alfentanil combination.

03

Conditions studied

  • Hypoxia
  • Infertility
  • Infertility Assisted Reproductive Technology

Keywords

  • Hypoxia
  • oocyte retrieval
  • remimazolam
  • general anesthesia
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 18 to 50 years planning to undergo painless oocyte retrieval
  • Subjects classified as (ASA) physical status I-II

Exclusion criteria

Exclusion Criteria:

  • Subjects with to general anesthesia, acute or severe cardiovascular disease history, acute upper respiratory infection, (COPD), asthma attacks, or uncontrolled hypertension
  • Subjects with alcohol abuse
  • Subjects with severe hepatic or renal insufficiency, severe cardiovascular disease, or psychiatric disorder history
  • Subjects with hearing impairment preventing communication
  • Subjects with a history of long-term sedative or opioid use, or allergies to benzodiazepines, flumazenil, opioids and their antidotes, propofol, eggs, or soy products
  • Subjects with SpO2 \< 95% while breathing room air after entering the room
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
400 participants (actual)

Study arms

  • Active comparator
    propofol-alfentanil

    Sedation using remimazolam-alfentanil

    Drug: propofol-alfentanil

  • Experimental
    remimazolam-alfentanil

    Sedation using remimazolam-alfentanil

    Drug: remimazolam-alfentanil combination

Interventions

  • Drugremimazolam-alfentanil combination

    Administer 7 μg/kg of alfentanyl first,then given remimazolam 0.2 mg/kg (1-minute bolus), followed by 1 mg/kg/h infusion.

  • Drugpropofol-alfentanil

    Administer 7 μg/kg of fentanyl first,then given propofol 2 mg/kg (1-minute bolus), followed by 6 mg/kg/h infusion.

06

What researchers measure

Primary outcomes

  1. Incidence of Hypoxia

    SpO₂ between 75% and 89% with duration \<60 seconds

    Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

Secondary outcomes

  1. Incidence of severe hypoxia

    SpO2 \< 75% or 75% ≤ SpO2 \< 90% for ≥60 s

    Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

  2. Incidence of subclinical respiratory depression

    90% ≤ SpO₂ \< 95%

    Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

  3. Proportion of hypoxic correction measures

    Corrective measures for hypoxia should be implemented in the following sequence: increase oxygen flow rate, perform jaw thrust, administer positive pressure ventilation via a face mask, insert a nasopharyngeal airway while performing jaw thrust, and proceed to endotracheal intubation or mechanical ventilation with a laryngeal mask until SpO₂ reaches ≥95%.

    Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

Other outcomes

  1. The incidence of other adverse events

    Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force

    Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

07

Study locations

2 sites
  • Dongyang People's Hospital
    Dongyang, Zhejiang 322100, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
08

References and documents

Publications

  • Zhang F, Chang H, Qing W, Yu R, Liao Q, Tong J. Remimazolam Tosylate Combined with Low-Dose Propofol Improves Sedation and Safety in Hysteroscopy. Drug Des Devel Ther. 2022 Nov 29;16:4101-4108. doi: 10.2147/DDDT.S390403. eCollection 2022. PubMed 36471692 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Sep 2026, 10 months.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 10 months is below that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2026 → Sep 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Jan 13, 2026
StartActual
Oct 20, 2025
Primary completionActual
Sep 1, 2026was Dec 2026
CompletionActual
Oct 1, 2026was Dec 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 16, 2026
Sites
1 site removed
Show 1 removed
  • Lishui People's Hospital · Lishui, China
Oct 16, 2026
Primary completion
Dec 20, 2026→Sep 1, 2026 (actual)
Oct 16, 2026
Study completion
Dec 30, 2026→Oct 1, 2026 (actual)
Oct 16, 2026
Title
The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Completed
    1 site removed
    Show 1 removed
    • Lishui People's Hospital · Lishui, China
    Primary completion Dec 20, 2026→Sep 1, 2026 (now actual)
    Study completion Dec 30, 2026→Oct 1, 2026 (now actual)
    Title The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.
    + 4 other changes: verification date, arm descriptions, contact details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07335536
Lead sponsor
Diansan Su
Responsible party
Diansan Su (Director of Anesthesiology, Zhejiang University) — Sponsor-investigator
First posted
Jan 13, 2026
Start date
Oct 20, 2025
Primary completion
Sep 1, 2026
Completion
Oct 1, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion